OMIC: Singular Genomics Systems, Inc. Price-to-Revenue Multiple
The rolling P/S of Singular Genomics Systems (OMIC) helps identify asset overheating, with 18.80 representing the current metric value. The Singular Genomics Systems (OMIC) business is protected by a complex NGS patent portfolio and strict FDA oversight. Production facilities consistently output analyzers featuring updated chip lithography. The firm's technologies automate laboratories, replacing manual labor with autonomous genetic sequencing.
Metric breakdowns and analytics for Singular Genomics Systems Inc (OMIC)
- share price and consensus valuation forecast:
- market capitalization information:
- book capitalization data:
- debt obligations and liquidity statistics:
Debt to Capital Singular Genomics Systems|OMIC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Singular Genomics Corp|OMIC - Company Aggregate Debts|Debts to Net Assets Singular Genomics Systems Inc|OMIC - Company Long-Term Debts|Company Current Liabilities Singular Genomics|Interim Coverage Ratio singulargenomics.com
- earnings and multiples data:
OMIC - Net Income|Expected Net Income Singular Genomics Systems|OMIC - Price to Earnings Ratio|Market Cap to Projected Earnings Singular Genomics Systems, Inc.|OMIC - Price/Earnings to Growth Multiple|Company Value to EBITDA Singular Genomics Systems Inc|OMIC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Singular Genomics|OMIC - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months singulargenomics.com|OMIC - Earnings growth in current year|Expected net earnings per share growth next year Singular Genomics Systems
- total revenue and sales volume data:
General company analysis:OMIC, singulargenomics.com
Amidst the fierce competition of Singular Genomics Systems (OMIC) against sequencing market monopolists, the current price-to-sales ratio reflects the market's valuation of the company's expansion potential. This metric is calculated as the ratio of market capitalization to annual revenue, allowing investors to determine the premium paid per unit of sales and assess business resilience during periods of high volatility and technological pressure from competitors.
Competing companies
TEM (Tempus AI) - Market Capitalization-to-Revenue Ratio|P/S Multiple QGEN (Qiagen)|Price-to-Revenue Multiple Ionis Pharmaceuticals, Inc.|Repligen Corp. - P/S Multiple|Price to Sales Avidity Corp|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio WGS|Price-to-Revenue Ratio Ultragenyx|Price to Sales Beam Therapeutics Inc BEAM|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Market Cap to Revenue Twist Bioscience Corp TWST|P/S Multiple TXG (10x Genomics, Inc.)|Price-to-Revenue Coefficient intelliatx.com (NTLA)|Stoke Therapeutics, Inc. - P/S Multiple|BioLife Solutions Inc (BLFS) - Market Cap to Revenue|Wave Life Sciences Corp (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|Market Cap to Revenue SION|PRME: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Price-to-Revenue Coefficient uniQure NV|MeiraGTx PLC - Market Cap to Revenue|REGENXBIO Corp (RGNX) - Price to Sales|SLDB - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ocugen.com OCGN|PACB (PacBio) - Market Cap to Revenue|BNTC: Market Cap to Sales Volume|DSGN (Design Pharma) - P/S Multiple|Price to Sales Rocket Corp RCKT|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|Market Cap to Revenue lexeotx.com LXEO|Price-to-Revenue Ratio Korro Bio KRRO|Price-to-Revenue Coefficient Editas Medicine Inc (EDIT)|SLN - Price-to-Revenue Ratio|Price to Sales ProQR Therapeutics N.V.|codexis.com (CDXS) - Price-to-Revenue Ratio|Market Cap to Revenue sangamo.com|NAUT (Nautilus Biotechnology, Inc.) - P/S Multiple|Metagenomi Inc. (MGX) - Price-to-Revenue Coefficient|P/S Multiple DTIL|Market Cap to Revenue generationbio.com GBIO|P/S Multiple BOLD (Boundless Bio, Inc.)|XCUR: Market Cap to Revenue Ratio|IMNN - Price-to-Revenue Ratio|PHIO (Phio Pharmaceuticals) - Market Cap to Revenue Ratio|MBIO: P/S Multiple|TransCode Therapeutics, Inc. (RNAZ) - P/S Multiple|Price-to-Revenue Ratio Bionano Genomics Inc.|adnas.com (APDN) - Price-to-Revenue Coefficient|P/S Multiple BLUE|Price-to-Revenue Coefficient immunoprecise.com|Price-to-Revenue Ratio Omega OMGA|RGLS: Market Cap to Revenue Ratio|Syros Pharmaceuticals - P/S Multiple|Price-to-Revenue Multiple telesisbio.com (TBIO)|TCON (TRACON Pharmaceuticals, Inc.) - Market Cap to Revenue|Unity Biotechnology Inc. (UBX) - P/S Multiple
